RESUMEN
The aim of this study was to explore the expression of PI3K, AKT, and P-AKT, and to investigate the role of PI3K/AKT signaling pathway in thin endometrium. We included 40 women treated in affiliated Shenzhen Nanshan People's Hospital of Guangdong Medical University for endometrial conditions between August 2013 and January 2015, 20 with a normal endometrium, and 20 with thin endometrium. The expression of PI3K, AKT, and P-AKT was evaluated by the immunohistochemical S-P method. The expression of PI3K, AKT, and P-AKT proteins was significantly lower in the thin endometrium group than in the normal endometrium group (P < 0.05). The expression of PI3K and AKT was positively correlated with the expression of P-AKT. The expression of PI3K, AKT, and P-AKT proteins in the thin endometrium decreases during the proliferative phase, and this process could be associated with PI3K/AKT signaling.
Asunto(s)
Endometrio/metabolismo , Fosfatidilinositol 3-Quinasas/genética , Fosfoproteínas/genética , Proteínas Proto-Oncogénicas c-akt/genética , Adulto , Estudios de Casos y Controles , Endometrio/patología , Congéneres del Estradiol/sangre , Femenino , Regulación de la Expresión Génica , Humanos , Fosfatidilinositol 3-Quinasas/sangre , Fosfoproteínas/sangre , Congéneres de la Progesterona/sangre , Proteínas Proto-Oncogénicas c-akt/sangre , Transducción de SeñalRESUMEN
CONTEXT: Estrogen levels and their metabolites are higher in obese vs lean postmenopausal women, and obesity increases breast cancer risk. Quinone derivatives of 4-hydroxylated estrogen metabolites, independently of the estrogen receptor, cause depurination and impaired DNA repair (genotoxic). 16α-Hydroxy (16α-OH)-estrone (E1), eg, promotes tumor proliferation and 2-methoxy-estradiol (E2) may be chemoprotective. Childhood obesity increases breast cancer death risk in women, but levels of estrogen derivatives had not been previously studied in young children. OBJECTIVE: The objective of the study was to investigate whether total and genotoxic estrogens are increased in prepubertal obese girls compared with lean controls. DESIGN: Stored sera from 12 lean and 23 obese prepubertal girls (Tanner stage I breast and pubic hair) studied previously were assayed for E1, E2, and their multiple metabolites (12 steroids total) using highly sensitive liquid chromatography and tandem mass spectrometry. RESULTS: E2 concentrations were significantly higher in obese [3.45 (0.5, 4.65) pg/ml (median [quartile 1, quartile 3])] vs lean girls [0.5 (0.5, 2.37), P = .04], 57% of values upper quartile or greater (quartile 3) of controls. Concentrations of 16α-OH-E1 were higher in obese [7.17 (0.5, 9.64) pg/mL] vs lean girls [0.5 (0.5, 1.72, P = .007)], 65% of values quartile 3 or greater of controls. 2-Methoxy-E2 concentrations were lower in the obese group (P = .012). 16α-OH-E1 concentrations were positively correlated with body mass index, percentage fat mass, and IL-6 concentrations (P < .001). CONCLUSIONS: E2 and genotoxic metabolites were higher in obese vs lean prepubertal girls. These data suggest that obesity is associated with an increased extraglandular estrogen production and metabolism before the onset of puberty in girls. Long-term epidemiological studies are needed to assess any potential increase in breast cancer risk.
Asunto(s)
Congéneres del Estradiol/sangre , Estrógenos/sangre , Mutágenos/metabolismo , Obesidad Infantil/sangre , 2-Metoxiestradiol , Estudios de Casos y Controles , Niño , Estradiol/análogos & derivados , Estradiol/sangre , Congéneres del Estradiol/metabolismo , Estriol/sangre , Estrógenos/metabolismo , Estrona/análogos & derivados , Estrona/sangre , Femenino , Humanos , Obesidad Infantil/metabolismo , Pubertad , Delgadez/sangre , Delgadez/metabolismo , Regulación hacia ArribaRESUMEN
Liquid chromatography-selected reaction monitoring/mass spectrometry-based methodology has evolved to the point where accurate analyses of trace levels of estrogens and androgens in postmenopausal serum and plasma can be accomplished with high precision and accuracy. A suite of derivatization procedures has been developed, which together with modern mass spectrometry instrumentation provide investigators with robust and sensitive methodology. Pre-ionized derivatives are proving to be useful as they are not subject to suppression of the electrospray signal. Postmenopausal women with elevated plasma or serum estrogens are thought to be at increased risk for breast and endometrial cancer. Therefore, significant advances in risk assessment should be possible now that reliable methodology is available. It is also possible to conduct analyses of multiple estrogens in plasma or serum. Laboratories that are currently employing liquid chromatography/mass spectrometry methodology can now readily implement this strategy. This will help conserve important plasma and serum samples available in Biobanks, as it will be possible to conduct high sensitivity analyses using low initial sample volumes. Reported levels of both conjugated and non-conjugated estrogen metabolites are close to the limits of sensitivity of many assays to date, urging caution in the interpretation of these low values. The analysis of serum androgen precursors in postmenopausal women has not been conducted routinely in the past using liquid chromatography/mass spectrometry methodology. Integration of serum androgen levels into the panel of metabolites analyzed could provide additional information for assessing cancer risk and should be included in the future.
Asunto(s)
Andrógenos/sangre , Cromatografía Liquida/métodos , Estrógenos/sangre , Posmenopausia/sangre , Espectrometría de Masas en Tándem/métodos , Congéneres del Estradiol/sangre , Congéneres del Estradiol/metabolismo , Estrógenos/metabolismo , Femenino , Cromatografía de Gases y Espectrometría de Masas/métodos , Humanos , Límite de Detección , Sensibilidad y Especificidad , Espectrometría de Masas en Tándem/instrumentaciónAsunto(s)
Alopecia/sangre , Andrógenos/sangre , Hormonas Esteroides Gonadales/sangre , Folículo Piloso/metabolismo , 3-Oxo-5-alfa-Esteroide 4-Deshidrogenasa/metabolismo , Inhibidores de 5-alfa-Reductasa/uso terapéutico , Alopecia/epidemiología , Alopecia/genética , Alopecia/fisiopatología , Alopecia/psicología , Alopecia/terapia , Animales , Comorbilidad , Costo de Enfermedad , Congéneres del Estradiol/sangre , Femenino , Predisposición Genética a la Enfermedad , Folículo Piloso/efectos de los fármacos , Folículo Piloso/fisiopatología , Folículo Piloso/trasplante , Humanos , Incidencia , Masculino , Fenotipo , Receptores Androgénicos/metabolismo , Factores de Riesgo , Factores Sexuales , Congéneres de la Testosterona/sangreRESUMEN
We report liquid chromatographic separation with tandem mass spectrometry determination of 12 endogenous estrogens and their intact conjugates in blood and urine and its application to study effects of exemestane treatment on estrogen generation and metabolism in postmenopausal women with estrogen-dependent breast cancer. A 0.5 mL aliquot of each urine or serum sample is fractionated with solid phase extraction to a fraction of free estrogen and another fraction of their conjugates. The reversed phase LC/MS/MS determines dansylated estrogens with positive ionization and intact conjugates with negative ionization. The method provides reproducible separation and limit of detection as low as 1 pg mL(-1) for free estrogens and 0.03 ng mg(-1) creatinine for the conjugates in serum and urine samples. The method enabled us to acquire unique concentration profiles of 12 endogenous estrogens and their intact conjugates in 30 breast cancer patients before and after one month of exemestane treatment. Exemestane suppressed total serum and urinary estrogens by 11-97% (P<0.0001) and 8.7-91% (P<0.0001), respectively. Specifically, these data show that exemestane preferentially suppressed E1, E1-3S, E1-3G, and E2-17G more than other estrogens. Linear regression analysis of estrogen concentrations before and after treatment showed correlation coefficients of 0.8385 (n=289, P<0.0001) and 0.8863 (n=360, P<0.0001). This study provides urinary and blood estrogen concentration profiles in breast cancer patients to demonstrate the effect of exemestane on estrogen generation, supporting inhibition of aromatase activity.
Asunto(s)
Androstadienos/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Cromatografía Líquida de Alta Presión , Congéneres del Estradiol/análisis , Estrógenos/análisis , Espectrometría de Masas en Tándem , Congéneres del Estradiol/sangre , Congéneres del Estradiol/orina , Estrógenos/sangre , Estrógenos/orina , Femenino , Humanos , Posmenopausia , Extracción en Fase SólidaRESUMEN
Ethylenethiourea (ETU) is the common metabolite of the widely used ethylenebisdithiocarbamate fungicides. It is identified as Endocrine Disruptor given its ability to interfere with thyroid hormone biosynthesis by inhibiting thyroid peroxidase activity. As far as we know, no studies have been performed to assess potential effects of ETU exposure at low dose levels, i.e. below the established LOAEL and NOAEL, during critical phases of development. Therefore, the aim of the present study was to verify the short- and long-term effects on thyroid function, reproduction and development of oral exposure to ETU levels comparable to and lower than LOAEL/NOAEL in rats. Sixty dams were treated daily by gavage during pregnancy and lactation with 0, 0.1, 0.3, 1.0 mg/kg bw per day of ETU. F1 generation was similarly treated from weaning to sexual maturity. Thyroid biomarkers were analyzed in dams and in offspring. Reproductive biomarkers were analyzed in F1 rats. For the first time this study has demonstrated reproductive toxicity and hypothyroidism at a lower than LOAEL dose exposure in pregnant dams and F1 generation. Our data suggest that even low doses of ETU can interfere with thyroid homeostasis and reproductive hormone profile if exposure starts in critical stages of development.
Asunto(s)
Disruptores Endocrinos/toxicidad , Etilenotiourea/toxicidad , Hipotiroidismo/inducido químicamente , Infertilidad Femenina/inducido químicamente , Infertilidad Masculina/inducido químicamente , Efectos Tardíos de la Exposición Prenatal , Glándula Tiroides/efectos de los fármacos , Administración Oral , Animales , Biomarcadores/sangre , Biomarcadores/metabolismo , Hipotiroidismo Congénito/inducido químicamente , Hipotiroidismo Congénito/fisiopatología , Relación Dosis-Respuesta a Droga , Disruptores Endocrinos/administración & dosificación , Congéneres del Estradiol/sangre , Etilenotiourea/administración & dosificación , Femenino , Fungicidas Industriales/metabolismo , Fungicidas Industriales/toxicidad , Hipotiroidismo/sangre , Hipotiroidismo/patología , Hipotiroidismo/fisiopatología , Infertilidad Femenina/sangre , Infertilidad Masculina/sangre , Lactancia , Masculino , Residuos de Plaguicidas/toxicidad , Embarazo , Ratas , Ratas Sprague-Dawley , Congéneres de la Testosterona/sangre , Glándula Tiroides/patología , Glándula Tiroides/fisiopatologíaRESUMEN
The actual levels of steroid hormones in organs are vital for endocrine, reproductive and neuronal health and disorders. We developed an accurate method to determine the levels of steroid hormones and steroid conjugates in various organs by an efficient preparation using a solid-phase-extraction cartridge. Each steroid was identified by the precursor ion spectra using liquid chromatography-electrospray ionization time-of-flight mass spectrometry, and the respective steroids were quantitatively analysed in the selected reaction monitoring mode by liquid chromatograph-mass spectrometry/mass spectrometry (LC-MS/MS). The data showed that significant levels of testosterone, corticosterone and precursors of both hormones were detected in all organs except liver. The glucuronide conjugates of steroid hormones and the precursors were detected in all organs except liver, but sulfate conjugates of these steroids were observed only in the target organs of the hormones and kidney. Interestingly, these steroids and the conjugates were not observed in the liver except pregnenolone. In conclusion, an accurate determination of tissue steroids was developed using LC-MS analysis. Biosynthesis of steroid hormones from the precursors was estimated even in the target organs, and the delivery of these steroid conjugates was also suggested via the circulation without any significant hepatic participation.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Corticosterona/análisis , Congéneres del Estradiol/análisis , Espectrometría de Masas en Tándem/métodos , Congéneres de la Testosterona/análisis , Glándulas Suprarrenales/química , Glándulas Suprarrenales/metabolismo , Animales , Calibración , Corticosterona/biosíntesis , Corticosterona/sangre , Corticosterona/metabolismo , Congéneres del Estradiol/biosíntesis , Congéneres del Estradiol/sangre , Congéneres del Estradiol/metabolismo , Glucurónidos/química , Glucurónidos/metabolismo , Riñón/química , Riñón/metabolismo , Límite de Detección , Hígado/química , Hígado/metabolismo , Masculino , Especificidad de Órganos , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Extracción en Fase Sólida , Espectrometría de Masa por Ionización de Electrospray , Sulfatos/química , Sulfatos/metabolismo , Testículo/química , Testículo/metabolismo , Congéneres de la Testosterona/biosíntesis , Congéneres de la Testosterona/sangre , Congéneres de la Testosterona/metabolismoRESUMEN
BACKGROUND: Despite the effective role of adiponectin levels in the predisposition to type 2 diabetes mellitus, the potential impact of adiponectin in manifest type 2 diabetes is less studied. OBJECTIVES: This study aimed to determine gender-specific differences regarding the relationship between adiponectin levels and metabolic parameters as well as sex hormones in elderly type 2 diabetics. METHODS: Sixty-two elderly type 2 diabetic men (mean age 60 [9] years) and 38 postmenopausal type 2 diabetic women (mean age 64 [9] years) were evaluated in a cross-sectional study. Glycemic control, lipids, sex hormones, adiponectin, and anthropometric parameters were measured in all participants. RESULTS: Serum adiponectin was higher in women than in men (P < 0.006). After controlling for age and body mass index, adiponectin concentrations showed a positive correlation with sex hormone-binding globulin and high-density lipoprotein levels (P < 0.001) and a negative correlation with glycated hemoglobin, homeostasis model assessment index for insulin resistance, glucose, C-peptide, and triglyceride levels (P < 0.05) in all patients. In men, adiponectin significantly correlated with serum levels of testosterone (r = 0.420; P < 0.002). In women, negative correlations were observed between adiponectin levels and the fatty liver index (r = -0.492; P < 0.006) and γ-glutamyltransferase (r = -0.432; P < 0.01). CONCLUSIONS: High serum adiponectin is a feature of better metabolic control and lipid profile, whereas low adiponectin levels are associated with fatty liver disease in women and low testosterone levels in men with type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Congéneres del Estradiol/sangre , Congéneres de la Progesterona/sangre , Congéneres de la Testosterona/sangre , Adiponectina/sangre , Adiponectina/metabolismo , Adulto , Factores de Edad , Índice de Masa Corporal , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Congéneres del Estradiol/metabolismo , Femenino , Hemoglobina Glucada , Humanos , Hipoglucemiantes/uso terapéutico , Masculino , Metformina/uso terapéutico , Persona de Mediana Edad , Congéneres de la Progesterona/metabolismo , Factores Sexuales , Globulina de Unión a Hormona Sexual , Estadística como Asunto , Congéneres de la Testosterona/metabolismoRESUMEN
INTRODUCTION: Sexual function in women in the reproductive age years is under psychological, sociocultural, and relationship influences, as well as the influence of sex hormones. AIM: To examine the data relating to sexual function in women in the reproductive age group, particularly the influence of sex hormones. To examine, in particular, the influence of the menstrual cycle, pregnancy, the oral contraceptive pill and endogenous and exogenous testosterone. METHODS: Review of the literature on female sexual function, confining the search to the reproductive age range. RESULTS: Population studies of sexual function identify sexual disinterest as being the most common sexual complaint in premenopausal women. Most studies of menstrual cyclicity identify a periovulatory increase in sexual desire or activity. All prospective studies of sexuality in pregnancy document a decline in sexual function with progression of pregnancy. Studies of the influence of the oral contraceptive pill on sexual function are contradictory with most prospective controlled studies showing no deleterious effect. Studies of the influence of endogenous androgens on sexuality are also contradictory with one large cross-sectional study showing no correlation, but some case-controlled studies show low androgens in women with sexual dysfunction. Studies of testosterone therapy in premenopausal women are ambiguous, with no clear dose-response effect. CONCLUSIONS: Sexual disinterest is prevalent in premenopausal woman despite being hormone replete. The assessment of androgen contribution is hampered by the unreliability of the testosterone assay in the female range. Large cross-sectional and longitudinal studies have not identified a correlation between testosterone and sexual function in women. Sexual dysfunction in the premenopausal age range is common. Sex hormones have a modifying effect on sexual function but social influences and learned responses are as important. The role of testosterone requires further study.
Asunto(s)
Congéneres del Estradiol/uso terapéutico , Libido , Congéneres de la Progesterona/uso terapéutico , Conducta Sexual , Disfunciones Sexuales Fisiológicas/fisiopatología , Factores de Edad , Congéneres del Estradiol/sangre , Femenino , Humanos , Embarazo , Prevalencia , Congéneres de la Progesterona/sangre , Factores Sexuales , Testosterona/sangreRESUMEN
A fast and sensitive LC-ESI-MS method is described for the comparative quantification of 16 estrogen metabolites based on the derivatization of estrogens with a novel derivatizing reagent, N-methyl-nicotinic acid N-hydroxysuccinimide ester (C1-NA-NHS). The process introduces a quaternary amine to the analytes, making the analytes permanently charged regardless of the pH of the high-performance liquid chromatography (HPLC) mobile phase. This quaternization resulted in a highly efficient separation of 16 estrogen metabolites in 7 min at a detection level below 1 ng/mL. By using a deuterated derivatizing reagent (C1-d(3)-NA-NHS), a complete set of deuterated standards was utilized and used as internal standards in a comparative quantification and recovery study, demonstrating acceptable results over a wide concentration range. A pooled breast cancer serum sample was analyzed using the described method, and 15 estrogens were detected in the range of 80-530 pg/mL.
Asunto(s)
Neoplasias de la Mama/sangre , Cromatografía Líquida de Alta Presión/métodos , Congéneres del Estradiol/análisis , Espectrometría de Masa por Ionización de Electrospray/métodos , Congéneres del Estradiol/sangre , Congéneres del Estradiol/química , Humanos , Marcaje Isotópico , Sensibilidad y EspecificidadRESUMEN
In postmenopausal women, levels of estrogens, androgens, and perhaps prolactin have been related to risk of breast and other hormonal cancers in women. However, the determinants of these hormone concentrations have not been firmly established. Associations among various demographic, menstrual, and reproductive factors, medication use and endogenous sex hormone concentrations (estradiol, free estradiol, estrone, estrone sulfate, testosterone, free testosterone, sex hormone binding globulin, androstenedione, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS), dihydrotestosterone, and prolactin) were evaluated in a cross-sectional analysis from a simple random sample of 274 postmenopausal women selected from the Women's Health Initiative Dietary Modification Trial. In multiple regression analyses on log-transformed hormones, the concentrations of DHEA, and DHEAS were negatively and statistically significantly associated with age (both beta=-0.03, P<0.001, respectively). Estradiol, estrone, DHEA, and free testosterone concentrations were higher in African-American than in non-Hispanic White women, but after multivariate adjustment the associations were statistically significant only for free testosterone (beta=0.38, P=0.01). Women who had a history of bilateral oophorectomy had a mean 35% lower testosterone concentration compared with women with at least one ovary remaining (beta=-0.43, P=0.002), and lower free testosterone (beta=-0.42, P=0.04) after multivariate adjustment. Women who reported regular use of NSAIDs had higher DHEA concentrations (beta=0.20, P=0.04) and lower prolactin concentrations (beta=-0.18, P=0.02) compared with non-users. These results suggest that while age, oophorectomy status, and NSAID use may be associated with selected sex hormone concentrations, few menstrual or reproductive factors affect endogenous sex hormones in the postmenopausal period.
Asunto(s)
Envejecimiento/sangre , Antiinflamatorios no Esteroideos/efectos adversos , Neoplasias de la Mama/etiología , Hormonas Esteroides Gonadales/sangre , Ciclo Menstrual , Posmenopausia/sangre , Reproducción , Negro o Afroamericano , Factores de Edad , Anciano , Neoplasias de la Mama/sangre , Neoplasias de la Mama/etnología , Neoplasias de la Mama/fisiopatología , Anticonceptivos Hormonales Orales/efectos adversos , Estudios Transversales , Congéneres del Estradiol/sangre , Terapia de Reemplazo de Estrógeno/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , Ovariectomía/efectos adversos , Prolactina/sangre , Factores de Riesgo , Congéneres de la Testosterona/sangre , Población BlancaRESUMEN
Mammographic density is an independent risk factor for breast cancer. In postmenopausal women, higher levels of endogenous sex steroids are associated with an increased risk of breast cancer. Limited prior data suggest that endogenous sex steroids either are not associated (total estradiol and progesterone) or are negatively associated (free estradiol) with higher mammographic density. To analyze the associations between endogenous sex steroids and mammographic density, the authors conducted a 1998-2005 cross-sectional analysis of baseline clinical trial data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial for US women who had not used hormone therapy for at least 3.1 months prior to baseline. In models adjusted for age, body mass index, parity, prior use of hormone therapy, time since last use of hormone therapy, and the interaction between prior hormone therapy use and time since last hormone therapy use, higher levels of estrone (beta = 0.0013, p = 0.014), estradiol (beta = 0.0009, p = 0.009), and bioavailable estradiol (beta = 0.0021, p = 0.018) were statistically significantly related to greater mammographic density. (Beta coefficients express the increment in mammographic density per-unit increment (pg/ml) of each hormone.) These results suggest that some sex steroids may increase the risk of breast cancer by stimulating breast epithelial or stromal proliferation, which appears on a mammogram as higher density.
Asunto(s)
Mama/anatomía & histología , Hormonas Esteroides Gonadales/sangre , Mamografía , Posmenopausia/sangre , Globulina de Unión a Hormona Sexual/metabolismo , Neoplasias de la Mama/etiología , Estudios Transversales , Congéneres del Estradiol/sangre , Femenino , Humanos , Persona de Mediana Edad , Progesterona/sangre , Factores de Riesgo , Testosterona/sangre , Estados UnidosRESUMEN
The extensive metabolism and administration of low doses of ethinylestradiol (EE) in preclinical animal species necessitates a sensitive analytical method to quantify the drug at low picogram-per-milliliter concentrations in biological matrixes. A highly sensitive and accurate method based on the derivatization of EE with dansyl chloride coupled with liquid chromatography/tandem mass spectrometry is described. The dansyl derivatization of EE introduced a basic secondary nitrogen into the molecule that was readily ionized in commonly used acidic HPLC mobile phases. The derivative showed an intense protonated molecular ion at m/z 530 under positive turbo ion spray ionization. The collision-induced dissociation of this ion formed a distinctive product at m/z 171, corresponding to the protonated 5-(dimethylamino)naphthalene moiety. The selected reaction monitoring, based on the m/z 530 --> 171 transition, was highly specific for EE, since no background signal was observed from blank plasma obtained from rhesus monkeys. The limit of detection, at a signal-to-noise ratio of 5, was 0.2 fg/mL EE spiked into blank plasma. This allowed for a lower limit of quantitation of 5 pg/mL using a 50-microL plasma sample and 10-microL injection of dansylated derivative into the CTC-PAL Leap autosampler coupled to a Sciex API 4000 mass spectrometer. Using fast-gradient liquid chromatography, the analyte peak eluted at 1.6 min. The validation results showed high accuracy (% bias < 4) and precision (% CV < 7.5) at broad linear dynamic ranges (0.005-20 ng/mL), using deuterated EE as internal standard. Therefore, the facile dansyl derivatization coupled with tandem mass spectral analysis allowed the development of a highly sensitive and specific method for quantitation of trace levels of EE in the plasma of rhesus monkeys dosed orally and intravenously with EE.
Asunto(s)
Congéneres del Estradiol/sangre , Etinilestradiol/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Animales , Compuestos de Dansilo/química , Femenino , Macaca mulatta , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray/normasRESUMEN
Physiological toxicokinetic (PT) models are used to simulate tissue burdens by chemicals in animals and humans. A prerequisite for a PT model is the knowledge of the chemical's distribution among tissues. This depends on the blood flow and also on the free fraction of the substance and its tissue:blood partition coefficients. In the present study we determined partition coefficients in human tissues at 37 degrees C for the two selected xenoestrogens bisphenol A (BA) and daidzein (DA), and their unspecific binding to human serum proteins. Partition coefficients were obtained by incubating blood containing BA or DA with each of the following tissues: brain, liver, kidney, muscle, fat, placenta, mammary gland, and adrenal gland. Blood samples were analysed by HPLC. For BA and DA, all partition coefficients in non-adipose tissues were similar (average values: BA 1.4, DA 1.2). However, the lipophilic properties of both compounds diverge distinctly. Fat:blood partition coefficients were 3.3 (BA) and 0.3 (DA). These values indicate that with the exception of fat both compounds are distributed almost equally among tissues. In dialysis experiments, the unspecific binding of BA and DA with human serum proteins was measured by HPLC. For BA, the total concentration of binding sites and the apparent dissociation constant were calculated as 2000 and 100 nmol/ml, respectively. Because of the limited solubility of DA, only the ratio of the bound to the free DA concentration could be determined and was found to be 7.2. These values indicate that at low concentrations only small percentages of about 5% (BA) and 12% (DA) are as unbound free fractions in plasma. Since only the unbound fraction can bind to the estrogen receptor, binding to serum proteins represents a mechanism that limits the biological response in target tissues.
Asunto(s)
Congéneres del Estradiol/farmacocinética , Isoflavonas/farmacocinética , Fenoles/farmacocinética , Animales , Compuestos de Bencidrilo , Proteínas Sanguíneas/metabolismo , Cromatografía Líquida de Alta Presión , Congéneres del Estradiol/sangre , Congéneres del Estradiol/metabolismo , Semivida , Humanos , Isoflavonas/sangre , Isoflavonas/metabolismo , Masculino , Modelos Biológicos , Fenoles/sangre , Fenoles/metabolismo , Unión Proteica , Ratas , Ratas Endogámicas F344 , Ratas Sprague-Dawley , Especificidad de la Especie , Distribución TisularRESUMEN
AIMS: To determine the pharmacokinetic profile of norelgestromin (NGMN) and ethinyloestradiol (EE) following application of the contraceptive patch, Evra/Ortho Evra, at each of four anatomic sites (abdomen, buttock, arm, and torso). METHODS: Thirty-seven healthy, nonpregnant women aged 20-45 years participated in this open-label, four-period crossover study. Subjects were randomized to one of four treatment (site of application) sequences. Each patch was worn for 7 days, with a 1 month washout between treatments. Blood samples were collected before and at various times up to 240 h after application of each patch. Serum samples were assayed for NGMN and EE by validated methods. RESULTS: The serum concentration reference ranges for NGMN and EE are 0.6-1.2 ng ml-1 and 25-75 pg ml-1, respectively, based on studies of the mean Cave of oral norgestimate 250 microg and EE 35 microg. For all application sites, mean concentrations of NGMN and EE remained within these ranges during the 7 day wear period. Absorption of NGMN and EE during patch application on the buttock, arm, and torso was equivalent. Absorption of NGMN and EE during patch application on the abdomen was approximately 20% less than observed for the other three sites, although mean serum concentrations were still within reference ranges. A previous study demonstrated therapeutic equivalence of patches worn on the abdomen vs other sites. CONCLUSIONS: Serum concentrations of NGMN and EE from the contraceptive patch remain within the reference ranges throughout the 7 day wear period, regardless of the site of application (abdomen, buttock, arm, or torso).
Asunto(s)
Anticonceptivos Orales Combinados/farmacocinética , Congéneres del Estradiol/farmacocinética , Etinilestradiol/farmacocinética , Administración Cutánea , Adulto , Área Bajo la Curva , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Orales Combinados/sangre , Estudios Cruzados , Esquema de Medicación , Combinación de Medicamentos , Congéneres del Estradiol/administración & dosificación , Congéneres del Estradiol/sangre , Etinilestradiol/administración & dosificación , Etinilestradiol/sangre , Etisterona/análogos & derivados , Femenino , Humanos , Persona de Mediana Edad , Norgestrel/análogos & derivados , OximasRESUMEN
A multiple-dose, placebo-controlled, randomized pharmacokinetic study was performed in 15 early (i.e., 1-3 years) postmenopausal women to evaluate the single and steady-state pharmacokinetics of 0.625 mg Cenestin (Synthetic Conjugated Estrogens, A) tablets, administered once daily for 90 days. Plasma concentration-time profiles for both total (conjugated and unconjugated) estrone and equilin, two major estrogens in Cenestin, were nearly superimposable between Day 1 (single dose) and Day 90 (multiple dose), indicating equivalent drug exposure from one dose to the next. For total estrone, the mean estimates of Cmax and AUC0-24 were 2.5 ng/ml and 35.0 ng x h/ml for Day 1 and 3.0 ng/ml and 39.8 ng x h/ml for Day 90, respectively. Similarly, Cmax and AUC0-24 mean values for total equilin were 1.4 ng/ml and 17.4 ng x h/ml after Day 1 and 1.5 ng/ml and 17.3 ng x h/ml after Day 90, respectively. The mean tmax value for total estrone was 8.3 hours on Day 1 and 8.6 hours on Day 90, indicating a slower rate of absorption. The average estimate for observed drug accumulation index for the 24-hour dosing interval was calculated to be 1.1 for total estrone and 1.0 for total equilin. These data, taken together, indicate a slow and steady rate of absorption, minimal drug accumulation at steady state, and consistent drug exposure between Cenestin doses.
Asunto(s)
Congéneres del Estradiol/administración & dosificación , Congéneres del Estradiol/farmacocinética , Terapia de Reemplazo de Estrógeno , Estrógenos Conjugados (USP)/administración & dosificación , Estrógenos Conjugados (USP)/farmacocinética , Adulto , Anciano , Área Bajo la Curva , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/farmacocinética , Método Doble Ciego , Equilina/sangre , Estradiol/sangre , Congéneres del Estradiol/sangre , Terapia de Reemplazo de Estrógeno/estadística & datos numéricos , Estrógenos Conjugados (USP)/sangre , Estrona/sangre , Femenino , Humanos , Persona de Mediana Edad , Posmenopausia/sangre , ComprimidosRESUMEN
The plasma sex steroid-binding protein (SBP) is believed to be involved in regulating circulating endogenous sex steroids as well as cellular signal transduction to nuclear steroid receptors in sex steroid-sensitive tissues. In this study, a variety of estrogen mimics (EMs), which may contribute to the endocrine disrupting effects observed in fish, were tested for the ability to interact with the rainbow trout plasma sex steroid-binding protein (rtSBP) either singly or in binary combinations. The EMs ethynylestradiol, diethylstilbestrol, 4-hydroxytamoxifen, genistein, zearalenone, 4-t-octylphenol, bisphenol A and o,p'-DDT were all able to displace 1,2,4,6,7-[3H]estradiol from the sex steroid-binding site at the rtSBP (K(d)=2.1+/-0.5 nM, B(max)=2963+/-303 fmol estradiol/mg protein) in a dose-dependent and competitive manner. The plastizicer n-butyl benzyl phthalate only displayed weak binding affinity for the rtSBP, whereas the pesticide dieldrin was not able to compete for the high affinity estradiol-binding sites in plasma. None of the compounds tested was able to clearly promote the binding of the others when given in combination, indicating that synergy did not occur at the ligand-SBP binding level. The rtSBP binding affinity for EMs ranged over several orders of magnitude, but were consistently lower than those for the endogenous sex steroids (about 10(2)-10(6) less potent). The results suggest that the presence of rtSBP may potentially modulate the bioavailability of EMs to estrogen receptors relative to each other and to the endogenous sex steroids themselves. Since the binding of the endogenous ligands is reversible, SBP-bound estrogens (or androgens) potentially may also become displaced by potent EMs.
Asunto(s)
Congéneres del Estradiol/metabolismo , Estrógenos/metabolismo , Oncorhynchus mykiss/sangre , Globulina de Unión a Hormona Sexual/metabolismo , Animales , Unión Competitiva , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Congéneres del Estradiol/sangre , Estrógenos/sangre , Femenino , Masculino , Transducción de SeñalRESUMEN
The primary objective of this open-label study was to determine the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE)following two consecutive applications of a contraceptive patch (ORTHO EVRA/EVRA). Twelve healthy women wore the first patch on their abdomen for 7 days and, after removal at 168 hours (day 7), wore a second patch for 10 days (i.e., 3 days beyond the intended 7-day wear period). Blood samples were collected before and at various times up to 456 hours (day 19) after application of the first patch for analysis of NGMN and EE. Mean serum concentrations of NGMN and EE remained within the reference ranges, 0.6 to 1.2 ng/ml and 25 to 75 pg/ml, respectively, during the entire 7-day wear period after application of the first patch and for 10 days after application of the second patch; reference ranges are based on studies with ORTHO-CYCLEN/ Cilest. No patch detached spontaneously. No subject discontinued or experienced a serious adverse event.
Asunto(s)
Anticonceptivos Orales Combinados/farmacocinética , Congéneres del Estradiol/farmacocinética , Etinilestradiol/farmacocinética , Administración Cutánea , Adolescente , Adulto , Área Bajo la Curva , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Orales Combinados/sangre , Combinación de Medicamentos , Congéneres del Estradiol/administración & dosificación , Congéneres del Estradiol/sangre , Etinilestradiol/administración & dosificación , Etinilestradiol/sangre , Etisterona/análogos & derivados , Femenino , Humanos , Norgestrel/análogos & derivados , Oximas , Factores de TiempoRESUMEN
BACKGROUND: A long-acting parenteral depot estrogen, polyestradiol phosphate (PEP), which has been in clinical use for several years in combination therapy, has been reevaluated pharmacokinetically and clinically as a single treatment. The present report describes a model predicting the effect on testosterone flux achieved with this estrogen drug. METHODS: Data on serum levels of estradiol and testosterone from a single-dose study, in prostate cancer patients as well as data from injections of 240 or 320 mg PEP each fourth week, were used for pharmacokinetic/dynamic modeling. RESULTS: Serum concentrations of estradiol were governed by a flip-flop mechanism when administered as PEP. An indirect-response model fitted to individual data showed a value of about 500 pmol estradiol/l serum to get a 50% suppression of serum testosterone concentrations. CONCLUSIONS: This model could successfully predict the serum levels of estradiol and testosterone after repeated injections at different doses and was also used to simulate the testosterone suppressing effect of a new dose regimen.
Asunto(s)
Congéneres del Estradiol/farmacocinética , Estradiol/análogos & derivados , Modelos Químicos , Neoplasias de la Próstata/tratamiento farmacológico , Testosterona/sangre , Estradiol/administración & dosificación , Estradiol/sangre , Estradiol/farmacocinética , Estradiol/uso terapéutico , Congéneres del Estradiol/administración & dosificación , Congéneres del Estradiol/sangre , Congéneres del Estradiol/uso terapéutico , Humanos , Concentración 50 Inhibidora , Inyecciones Intramusculares , Masculino , Próstata/efectos de los fármacosRESUMEN
OBJECTIVE: To investigate whether the use of an oral contraceptive would influence plasma levels of budesonide (Entocort capsules) or prednisolone (plain tablets) during repeated oral administration of these glucocorticosteroids. Plasma concentrations of cortisol and ethinyl estradiol (INN, ethinylestradiol) were also compared. METHODS: Forty healthy women took part in this single-blind, randomized placebo-controlled study with two parallel groups, where a three-way crossover design was applied within groups. One group was taking an oral contraceptive (150 microg desogestrel and 30 microg ethinyl estradiol); the other group (control) was not. On seven consecutive mornings, oral doses of 4.5 mg budesonide, 20 mg prednisolone, or placebo were administered. There was a washout period of at least one menstrual cycle between administration periods. RESULTS: In the oral contraceptive users, the average plasma concentration of prednisolone was 131% higher than in the control group (P < .001), whereas the average plasma concentration of budesonide was only 22% higher (not significant). Mean plasma cortisol levels were suppressed by 90% and 82% with prednisolone and by 22% and 28% with budesonide in oral contraceptive users and the control subjects, respectively. The group difference was significant with prednisolone (P < .001) but not with budesonide. Ethinyl estradiol levels in plasma were not affected by administration of either glucocorticosteroid. CONCLUSION: No difference was found in plasma levels of budesonide or in cortisol suppression after administration of budesonide capsules in women taking the oral contraceptive and those who were not. The oral contraceptive users had much higher plasma levels of prednisolone and greater cortisol suppression. This result suggests that oral budesonide can be used with maintained safety in women using oral contraceptives.